# ArrePath

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arrepath

- Industry: Biotechnology
- Headquarters: US
- Website: www.arrepath.com
- Total disclosed funding: $20M
- Latest round: Seed (Mar 3, 2022)
- Investors on record: 7

## About

Based in New Jersey, US, and founded by its Chairman Zemer Gitai, ArrePath operates as an anti-infective drug discovery company.In June 2025, ArrePath, Inc. raised an undisclosed amount of venture funding led by new investor Boehringer Ingelheim Venture, with participation from another new investor AB Magnitude Ventures Group. Returning investors Insight Partners, Innospark Ventures, and Nor'easter Ventures also participated in the round. The company provides an advanced machine learning (ML) and imaging-based drug discovery platform to identify new classes of antibiotics. It also provides drug discovery, microbiology, microscopy, and data science to develop life-saving anti-infectives. It offers phenotypic profiling and bacterial autopsies, artificial intelligence/machine learning-enabled drug design, multidimensional phenotypic screening, and proteomics. The company plans to utilize the June 2025 funding to harness innovative technologies and methodologies to speed up delivering advanced solutions to market.

## Funding rounds

- Seed, Mar 3, 2022, $20M — Insight Partners, Boehringer Ingelheim Venture, Innospark Ventures, Viva BioInnovator, PTX Capital, Arimed Capital, Nor'easter Ventures

## Investors

- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Seed
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Seed
- Innospark Ventures (https://capitalatlas.ai/funds/innospark-ventures) — Seed
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Seed
- PTX Capital (https://capitalatlas.ai/funds/ptx-capital) — Seed
- Arimed Capital — Seed
- Nor'easter Ventures (https://capitalatlas.ai/funds/nor-easter-ventures) — Seed